Bryan Johnson’s Psilocybin Longevity Experiment: Testing Psychedelics for Anti-Aging
Last reviewed and updated: June 24, 2026.
Key Takeaways
| Bryan Johnson | Publicly documented psilocybin + biomarker tracking as part of Blueprint longevity protocol; self-experiment, not clinical trial |
| Strongest mechanism | BDNF promotion + neuroplasticity — BDNF declines with age; psilocybin reliably raises BDNF in animals and humans |
| Inflammation link | Psilocybin shows anti-inflammatory effects via 5-HT2A signaling; relevant to “inflammaging” — chronic low-grade inflammation driving aging disease |
| Evidence status | Plausible mechanisms; no long-term human longevity trial; anti-aging application at hypothesis/preclinical stage |
| Micro vs macro | Microdosing evidence mixed (placebo confound in trials); macrodosing (full doses) has stronger efficacy signals; longevity biohackers focus on macrodosing |
Bryan Johnson, the biohacking entrepreneur known for his extreme anti-aging protocols, announced this week that he will test psilocybin as a longevity therapy. His approach combines ancient medicine with cutting edge biomarker tracking to determine whether psychedelics can genuinely slow biological aging.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Key Protocol Elements
| Element | Details |
|---|---|
| Dosage | 5 grams dried mushrooms monthly (25-50 mg psilocybin) |
| Duration | 3 months |
| Primary Measurements | DNA methylation, telomere length, brain imaging, blood proteomics |
| Brain Tracking | Kernel Flow brain interface monitoring before, during, and after |
| Assessment Areas | Cellular aging, brain structure, cognitive function, mood |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
The Scientific Foundation
Recent research suggests psilocybin might extend lifespan at the cellular level. Studies show the compound increased survival in aged mice and enhanced cellular lifespan in human fibroblasts. The active metabolite, psilocin, appears to delay cellular senescence while preserving telomere length.
These findings move beyond established mental health benefits. Researchers observed that treated cells maintained their capacity to divide without showing cancerous changes. The compound also activated antioxidant pathways and DNA damage response systems that typically decline with age.
RELATED: “Don’t Die” Biohacker Bryan Johnson Considers Ketamine as Latest Anti-Aging Tool
Measuring Rejuvenation
Johnson plans comprehensive biomarker tracking throughout his experiment. DNA methylation analysis will reveal his biological age and individual organ aging rates. Telomere measurements will assess cellular regeneration capacity. Brain MRIs will capture structural changes and calculate brain age.
The Kernel Flow brain interface adds real time cortical activity monitoring. This technology will track how psilocybin affects neural function during each session. Blood panels will measure markers of cellular senescence, inflammation, and neuronal health.
Beyond Mental Health
A recent preprint demonstrated that psilocybin increased cortical entropy during peak effects. This brain state change predicted structural improvements visible on MRI scans one month later. Participants reported enhanced wellbeing and cognitive flexibility that persisted weeks after a single dose.
The neuroplasticity effects appear particularly striking. Even one high dose session can produce rapid antidepressant effects that last months. Cognitive performance improvements have emerged in preliminary studies, suggesting benefits extend beyond mood regulation.
Johnson’s experiment tests whether these brain changes translate into measurable longevity gains. His rigorous tracking protocol may provide the clearest picture yet of psilocybin’s anti-aging potential.
Psilocybin and Longevity: What the Science Actually Says About Anti-Aging Claims
Bryan Johnson’s public documentation of his psilocybin experiment drew significant attention to the intersection of psychedelics and longevity research. Here is what the underlying science supports and where it is more speculative.
The neuroplasticity connection: the most plausible mechanism. Psilocybin’s most well-documented biological effect relevant to aging is its promotion of neuroplasticity — specifically, the upregulation of BDNF (brain-derived neurotrophic factor), increased synaptogenesis (new synapse formation), and enhanced dendritic spine density. BDNF declines with age, and this decline is associated with cognitive aging and increased susceptibility to depression and neurodegenerative disease. Psilocybin consistently increases BDNF in animal studies and in human research. The claim that this translates to meaningful anti-aging effects in humans is plausible as a hypothesis but not yet confirmed — there are no long-term human trials specifically studying psilocybin as a longevity intervention. What exists is a strong mechanistic rationale and early supportive data from adjacent research (neurodegeneration, depression, cognitive function).
Inflammation: the emerging link. Chronic low-grade inflammation (sometimes called “inflammaging”) is increasingly recognized as a central driver of aging-related disease. Psilocybin and other classic psychedelics have shown anti-inflammatory effects in both preclinical and some human research — primarily through 5-HT2A receptor signaling, which modulates inflammatory cytokine production. A 2024 study found psilocybin reduced inflammatory markers in a human clinical population. This is an active research area and represents a more recent line of evidence than neuroplasticity for psilocybin’s potential relevance to aging biology.
What biohackers are actually doing vs. what’s studied. Bryan Johnson’s protocol — like most biohacker psilocybin use — involves macrodosing (full psychedelic doses) rather than microdosing. The longevity community has been more focused on macrodosing for specific planned sessions than on the microdosing trend. The scientific literature on microdosing is mixed — several placebo-controlled trials have shown limited effects distinguishable from expectancy. Macrodosing research (at therapeutic doses producing perceptible experiences) has stronger efficacy signals for depression, anxiety, and potentially neuroplasticity. Johnson’s public self-experimentation is not a controlled trial — it contributes to visibility and anecdote but not to the evidence base in the same way peer-reviewed research does.
Frequently Asked Questions
What is Bryan Johnson’s psilocybin experiment?
Bryan Johnson — the tech entrepreneur known for his Blueprint longevity protocol, which involves extremely rigorous diet, sleep, and supplementation tracking — publicly documented psilocybin use as part of his anti-aging experimentation. Johnson has shared data from his sessions, describing measuring biomarkers before and after psilocybin use to track any detectable biological changes. His experiment is self-experimentation (n=1), not a controlled clinical trial, but his platform and transparency have brought significant public attention to the question of whether psilocybin could be a longevity tool. Johnson is one of several prominent figures in the tech/longevity community who have publicly used and discussed psilocybin.
Can psilocybin slow aging?
There is no established evidence that psilocybin slows aging in humans. What the research does support: (1) psilocybin promotes BDNF and neuroplasticity, which decline with age and are associated with cognitive aging and neurodegenerative susceptibility; (2) psilocybin has anti-inflammatory effects that may be relevant to “inflammaging”; (3) psilocybin consistently improves depression and psychological wellbeing, which are themselves associated with longevity outcomes. These mechanisms provide a plausible biological rationale for further research, but no long-term human trial has tracked psilocybin against aging biomarkers or longevity outcomes. The anti-aging application is at the hypothesis and preclinical stage — promising but not established.
What does BDNF have to do with aging and psilocybin?
BDNF (brain-derived neurotrophic factor) is a protein that supports the growth, maintenance, and survival of neurons. BDNF levels decline with age, and low BDNF is associated with cognitive decline, depression, and increased risk of neurodegenerative diseases including Alzheimer’s and Parkinson’s. Psilocybin reliably increases BDNF in animal studies and has shown BDNF-promoting effects in human research. The theoretical longevity relevance: if BDNF decline is a driver of cognitive aging, and psilocybin promotes BDNF, then periodic psilocybin use could theoretically support cognitive aging trajectories. This is a plausible hypothesis and an active area of research — but not a proven intervention for human brain aging.
Is microdosing psilocybin proven to improve health or cognition?
The evidence for microdosing is more mixed than popular coverage suggests. Several controlled, placebo-blinded studies have found that the benefits reported by microdosers are largely not distinguishable from placebo effects — meaning expectation (believing you are taking psilocybin) accounts for much of the perceived benefit. That said, some studies have found specific cognitive or mood effects at sub-perceptual doses. The research is genuinely ongoing and the picture is not fully clear. In contrast, full-dose (macrodose) psilocybin research has much stronger and more consistent efficacy signals, particularly for depression and anxiety. Most longevity-focused researchers and biohackers are more interested in macrodosing than microdosing for biological effects.
